ReviewCells2021
Mechanisms of Neurodegeneration in Various Forms of Parkinsonism-Similarities and Differences.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Retina thickness in atypical parkinsonism: a systematic review and meta-analysis.Journal of neurology · 2022Pooled it
- Lipid Metabolism in Central Nervous System Diseases: Pathological Mechanisms and Therapeutic Advances.CNS neuroscience & therapeutics · 2026Review
- A narrative review of serum biomarkers in progressive supranuclear palsy, corticobasal syndrome, and related disorders.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Review
- Article
- Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.International journal of molecular sciences · 2025Article
- Neuromotor rehabilitation in Parkinsonian syndromes: outcomes and disability after hip fracture.European journal of medical research · 2025Article
- Parkinson's Disease: Bridging Gaps, Building Biomarkers, and Reimagining Clinical Translation.Cells · 2025Review
- Understanding the Pre-Clinical Stages of Parkinson's Disease: Where Are We in Clinical and Research Settings?International journal of molecular sciences · 2025Review
- Role of the Intestinal Microbiota in the Molecular Pathogenesis of Atypical Parkinsonian Syndromes.International journal of molecular sciences · 2025Review
- Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.Diagnostics (Basel, Switzerland) · 2025Article
- The Significance of High-Density Lipoprotein-Derived Inflammatory Parameters in Atypical Parkinsonisms-Pilot Study.Journal of clinical medicine · 2025Article
- Identification of Parkinson's disease using MRI and genetic data from the PPMI cohort: an improved machine learning fusion approach.Frontiers in aging neuroscience · 2025Article
- The role of neuron-like cell lines and primary neuron cell models in unraveling the complexity of neurodegenerative diseases: a comprehensive review.Molecular biology reports · 2024Review
- Asymmetry in Atypical Parkinsonian Syndromes-A Review.Journal of clinical medicine · 2024Review
- The Role of Magnesium in Parkinson's Disease: Status Quo and Implications for Future Research.International journal of molecular sciences · 2024Review
- MicroRNA-124-3p Modulates Alpha-Synuclein Expression Levels in a Paraquat-Induced in vivo Model for Parkinson's Disease.Neurochemical research · 2024Article
- Vocal Fold Motion Impairment in Neurodegenerative Diseases.Journal of clinical medicine · 2024Review
- The associations between common neuroimaging parameters of Progressive Supranuclear Palsy in magnetic resonance imaging and non-specific inflammatory factors - pilot study.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD), dementia with Lewy body (DLB), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA) belong to a group of neurodegenerative diseases called parkinsonian syndromes. They share several clinical, neuropathological and genetic features. Neurodegenerative diseases are characterized by the progressive dysfunction of specific populations of neurons, determining clinical presentation. Neuronal loss is associated with extra- and intracellular accumulation of misfolded proteins. The parkinsonian diseases affect distinct areas of the brain. PD and MSA belong to a group of synucleinopathies that are characterized by the presence of fibrillary aggregates of α-synuclein protein in the cytoplasm of selected populations of neurons and glial cells. PSP is a tauopathy associated with the pathological aggregation of the microtubule associated tau protein. Although PD is common in the world's aging population and has been extensively studied, the exact mechanisms of the neurodegeneration are still not fully understood. Growing evidence indicates that parkinsonian disorders to some extent share a genetic background, with two key components identified so far: the microtubule associated tau protein gene (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.